ATRC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AtriCure Inc (ATRC) is not a strong buy for a beginner investor with a long-term focus at this time. The stock faces significant competitive pressures, insider selling, and a recent downgrade by analysts. While the company has shown revenue growth, its net income and EPS have significantly declined. Additionally, technical indicators and trading signals do not suggest a strong entry point. It is best to hold off on investing in this stock until there is more clarity on its ability to compete and improve financial performance.
The MACD is negative and expanding, indicating bearish momentum. RSI is at 20.607, suggesting the stock is oversold but not providing a clear buy signal. Moving averages are converging, showing no strong trend. The stock is trading near its key support level of 31.978, with resistance at 34.977.
Gross margin improved slightly to 75.47%.
JPMorgan downgraded the stock from Overweight to Neutral, citing competitive pressures from Edwards Lifesciences and Medtronic. Insider selling has increased by 521.10% over the last month. The company's net income and EPS have significantly declined, and the stock dropped 15% following the downgrade.
In Q3 2025, revenue increased by 15.84% YoY to $134.27M. However, net income dropped by 96.60% YoY to -$267K, and EPS fell by 94.12% YoY to -$0.01. Gross margin improved slightly to 75.47%.
JPMorgan downgraded the stock to Neutral from Overweight, lowering the price target from $48 to $36. Analysts are concerned about competitive pressures from Edwards Lifesciences and Medtronic, which may impact AtriCure's market share and growth potential.
